Neon Therapeutics Inc (NASDAQ:NTGN) Receives $16.83 Average Target Price from Brokerages
Neon Therapeutics Inc (NASDAQ:NTGN) has received a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $16.57.
NTGN has been the topic of a number of research reports. Mizuho set a $21.00 price target on Neon Therapeutics and gave the stock a “buy” rating in a report on Monday, July 1st. Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Tuesday, July 16th. Robert W. Baird initiated coverage on shares of Cue Biopharma in a research report on Thursday. They issued an “outperform” rating and a $13.00 price objective for the company. HC Wainwright restated a “buy” rating on shares of CytRx in a research report on Tuesday, July 16th. Finally, Morgan Stanley reduced their price objective on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a research report on Tuesday, July 16th.
A number of large investors have recently made changes to their positions in NTGN. Marshall Wace North America L.P. acquired a new stake in shares of Neon Therapeutics during the 1st quarter valued at approximately $49,000. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Neon Therapeutics by 100.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after acquiring an additional 5,000 shares during the period. Rhumbline Advisers acquired a new stake in shares of Neon Therapeutics during the 1st quarter valued at approximately $78,000. Bank of New York Mellon Corp lifted its position in shares of Neon Therapeutics by 17.6% during the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock valued at $98,000 after acquiring an additional 2,905 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after acquiring an additional 6,493 shares during the period. Hedge funds and other institutional investors own 69.57% of the company’s stock.
Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.03). As a group, analysts anticipate that Neon Therapeutics will post -2.69 earnings per share for the current year.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Further Reading: Swap
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.